Amgen Inc - Depreciation and Amortization Expense

Amgen Inc's Fiscal Year is From January To December - All Figures are in USD, Billions.

The item "Depreciation-and-Amortization-Expense" stands at 5.43 Billion United States Dollars for the trailing twelve months (TTM) period ending 09/30/2025, the lowest value since 09/30/2024.

Amgen Inc's third quarter result of 1.31 Billion USD for the item "Depreciation and Amortization Expense" represents a decrease of -2.54 percent compared to it's second quarter result.

Also, Amgen Inc's third quarter result of 1.31 Billion USD for the item "Depreciation and Amortization Expense" represents a decrease of -6.38 percent compared to it's third quarter result of last year.

Looking again at the trailing twelve months series (TTM), Amgen Inc's third quarter result of 5.43 Billion USD for the item "Depreciation and Amortization Expense" represents a decrease of -1.61 percent compared to it's second quarter result.


Regarding the One-Year-Change of the series, the current value constitutes a decrease of -2.57 percent compared to the value the year prior.
The 1 year change in percent is -2.57.
The 3 year change in percent is 61.76.
The 5 year change in percent is 58.37.
The 10 year change in percent is 159.78.

The Serie's long term average value is 2.68 Billion United States Dollars. It's latest available value, on 09/30/2025, is 102.47 percent higher, compared to it's long term average value.
The Serie's change in percent from it's minimum value, on 03/31/2012, to it's latest available value, on 09/30/2025, is +419.31%.
The Serie's change in percent from it's maximum value, on 12/31/2024, to it's latest available value, on 09/30/2025, is -2.86%.